Aminopterin - Genzyme Oncology

Drug Profile

Aminopterin - Genzyme Oncology

Alternative Names: Aminopterin sodium

Latest Information Update: 04 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ILEX Oncology Inc
  • Developer Genzyme Oncology
  • Class Benzamides; Glutamates; Pterins; Small molecules
  • Mechanism of Action Antimetabolites; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Endometrial cancer; Leukaemia

Most Recent Events

  • 18 Sep 2018 Genzyme withdraws a phase II trial for Endometrial Cancer prior to enrolment in USA, before September 2018 (NCT00003821)
  • 31 Dec 2010 No development reported - Phase-II for Endometrial cancer in USA (PO)
  • 31 Dec 2010 No development reported - Phase-II for Leukaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top